Population‐based prevalence, type‐ and age‐specific distribution of HPV in women before introduction of an HPV‐vaccination program in Denmark
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Knowledge about the prevalence of human papillomavirus (HPV) on a population level is important. We conducted a large population‐based study in Denmark to determine the overall and age‐specific HPV prevalence, and HPV type distribution in women. Liquid‐based cytology samples (SurePath®) were collected consecutively. HPV testing was performed with Hybrid Capture 2 (HC2; Digene) (high‐risk and low‐risk probes), and LiPA (Innogenetics) was used for genotyping. We analyzed samples from 11,617 women; 94.0% had normal cytology, 4.3% atypical squamous cells of undetermined significance or low‐grade squamous intraepithelial lesion and 1.6% had high‐grade squamous intraepithelial lesion (HSIL). The HPV prevalence was 26.4% with a peak in women 20–24 years (50.2%) and then decreased without a second peak in older women. Among the youngest women (15–19 years), 14% had HPV 16/18 and 16% had HPV 6/11. Prevalence of high‐risk HPV types increased from 19.2% in women with normal cytology to 100% in women with cervical intraepithelial neoplasia grade 3 (CIN3)/cervical cancer. HPV 16 was the most prevalent type (6.0% of all women), and was also the most prevalent in women with HSIL (35.1%) and CIN3 (53.2%). Other common HPV types in women with CIN3 included HPV 52, 51, 31, 33 and 18. HPV 16/18 alone was present in 23% of CIN3 lesions and 67% of cervical cancers, and HPV 16/18 together with other high‐risk HPV types was present in 41% of CIN3 lesions. This suggests that an efficacious HPV 16/18 vaccine will have a substantial preventive potential in the general female population. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Chapter 1: HPV in the etiology of human cancer
Muñoz, N., Castellsagué, X., de González, A. B., & Gissmann, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.115 · Cited by 1,355
Cited by
Muñoz, N., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp534 · Cited by 566
Rebolj, M., Preisler, S., Ejegod, D. M., Rygaard, C., Lynge, E., & Bonde, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086835 · Cited by 74
HPV genotype distribution according to severity of cervical neoplasia
Sjoeborg, K. D., Tropé, A., Lie, A. K., Jonassen, C. M., Steinbakk, M., Hansen, M., Jacobsen, M. B., Cuschieri, K., & Eskild, A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.03.007 · Cited by 54
“In a crosssectional study in Denmark, comparing women with normal cytology andwomenwith CIN3+, HPV16/18was associatedwith two hundredfold higher risk of CIN3+ compared to being HPV DNA negative [26].”
ResultMartins, T. R., Mendes de Oliveira, C., Rosa, L. R., de Campos Centrone, C., Rodrigues, C. L. R., Villa, L. L., & Levi, J. E. (2016) · Virology Journal · doi:10.1186/s12985-016-0594-3 · Cited by 42
Metadata
- Authors
- Kjær, S. K., Breugelmans, G., Munk, C., Junge, J., Watson, M., & Iftner, T.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-08-13
- Volume
- 123
- Issue
- 8
- Pages
- 1864-1870
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1991640469
- Cited by
- 171
- References
- 3
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.